Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers

BACKGROUND: Larotrectinib is the first tumour-agnostic therapy that has been approved by the European Medicines Agency. Tumour-agnostic therapies are indicated for a multitude of tumour types. The economic models supporting reimbursement submissions of tumour-agnostic therapies are complex because o...

Descripción completa

Detalles Bibliográficos
Autores principales: Michels, Renée E., Arteaga, Carlos H., Peters, Michel L., Kapiteijn, Ellen, Van Herpen, Carla M. L., Krol, Marieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385762/
https://www.ncbi.nlm.nih.gov/pubmed/35843997
http://dx.doi.org/10.1007/s40258-022-00740-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385762/
https://www.ncbi.nlm.nih.gov/pubmed/35843997
http://dx.doi.org/10.1007/s40258-022-00740-1

Ejemplares similares